Efficacy of Extracorporeal Shock Wave Therapy on Spasticity
NCT ID: NCT06225024
Last Updated: 2024-02-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2022-03-15
2023-06-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Materials and Method: Patients with post-stroke ankle plantar flexor spasticity of 1 or more on the modified Ashworth Scale(MAS) were randomized into two groups.
Group 1(n:20): BoNT-A was injected into the gastrocnemius muscle and conventional physical therapy exercises were performed.
Group 2(n:20): ESWT was applied to the gastrocnemius muscle in addition to the treatments in group 1.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Botulinum Toxin Injection Combined with RESWT in Lower Extremity Spasticity in Children with Cerebral Palsy
NCT06494618
Does ESWT With BoNTA Treatment Improve Outcomes When Compared to Standard Management for Upper Limb Spasticity Patient.
NCT05226637
The Effect of Ultrasound-Guided Botulinum Toxin Injections on Pain, Functionality, Spasticity, and Range of Motion in Patients With Post-Stroke Upper Extremity Spasticity
NCT05887479
Comparing the Radial Extracorporeal Shock Waves and Botulinum Toxin Injection for Spasticity
NCT03131791
Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity
NCT02358005
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Group 2 (n:20): In addition to the treatments (BoNT-A injection and exercise) in Group 1, one week after the injection, a total of 4 sessions (2 days a week) of ESWT (1000 impulses with an energy density of 0.1 mj/mm2, pressure of 2 bar, and frequency of 4 Hz) were applied to the medial and lateral heads of the gastrocnemius muscle.
The patients in both groups underwent the following evaluations before treatment, at one month and three months after treatment by a treatment-blinded Physical Medicine and Rehabilitation (PMR) physician.
Patients' age, sex, occupation, hemiplegic sides, and etiology of hemiplegia were recorded. Physical examination was performed, and examination findings were recorded. The presence of post-treatment pain, redness, tenderness, or other adverse findings were questioned.
MAS, Brunnstrom Motor Recovery Stage(BMRS), ankle range of motion(ROM) measurement, clonus score(CS), Barthel Index(BI), Heckmatt measurements with ultrasonography, and visual analog scale(VAS) evaluations were performed on the patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
1. Modified Ashworth Scale (MAS)
2. Brunnstrom Motor Recovery Stage (BMRS)
3. Ankle range of motion (2) measurement
4. Clonus score (CS)
5. Barthel Index (BI)
6. Heckmatt measurements with ultrasonography
7. Visual analog scale (VAS) pain assessment.
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BoNT-A
BoNT-A was injected into the affected gastrocnemius muscle under ultrasonography guidance at doses recommended by standard guidelines and appropriate for the patient (50 IU to the medial head, 25 IU to the lateral head). In addition, conventional physical therapy exercises (stretching exercises, range of motion (ROM) exercises, neurophysiologic exercises, and gait exercises) were applied to the patients five days a week for four weeks.
BoNT A
BoNT-A is widely recognized as the benchmark for enhancing the effectiveness of spasticity management
BoNT-A and ESWT
In addition to the treatments (BoNT-A injection and exercise) in Group 1, one week after the injection, a total of 4 sessions (2 days a week) of ESWT (1000 impulses with an energy density of 0.1 mj/mm2, pressure of 2 bar, and frequency of 4 Hz) were applied to the medial and lateral heads of the gastrocnemius muscle.
ESWT
Extracorporeal shock wave therapy (ESWT) is a treatment method based on high-intensity sound waves focusing on the desired body area to provide treatment. ESWT is a safe, non-invasive, alternative treatment for spasticity in patients with stroke, cerebral palsy, and multiple sclerosis and does not cause muscle weakness or adverse effects
BoNT A
BoNT-A is widely recognized as the benchmark for enhancing the effectiveness of spasticity management
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ESWT
Extracorporeal shock wave therapy (ESWT) is a treatment method based on high-intensity sound waves focusing on the desired body area to provide treatment. ESWT is a safe, non-invasive, alternative treatment for spasticity in patients with stroke, cerebral palsy, and multiple sclerosis and does not cause muscle weakness or adverse effects
BoNT A
BoNT-A is widely recognized as the benchmark for enhancing the effectiveness of spasticity management
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Having a stroke confirmed by computed tomography (CT) and magnetic resonance imaging (MRI)
* Being aged over 18 years
* Having a MAS score of 1 and above for gastrocnemius, the plantar flexor muscle of the ankle
* Having a stable general condition after a stroke
* Giving consent to participate in the study.
Exclusion Criteria
* Having no spasticity in the soleus, the plantar flexor muscle of the ankle
* Previous antispastic surgery performed on the area
* Change in antispastic drug use in the last six months, if any
* Injection of BoNT-A, alcohol, phenol, or any other substance into the area in the last six months
* Active infection or cancer at the application site
* Having a cardiac pacemaker
* Having bleeding diathesis
* Having vascular complaints such as deep vein thrombosis, venous stasis, phlebitis, arterial disease
* Being pregnant
* Having neuromuscular junction disease or motor neuron disease
* Having a known allergy to BoNT-A
* 12\. Active use of aminoglycosides or other antibiotic groups.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Saglik Bilimleri Universitesi
OTHER
Kayseri City Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Havva Talay Çalış
Prof
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
HAVVA TALAY ÇALIŞ
Role: PRINCIPAL_INVESTIGATOR
KAYSERİ CITY HOSPITAL
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Health Sciences University, Kayseri Medicine Faculty
Kayseri, Kocasinan, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Yoldas Aslan S, Kutlay S, Dusunceli Atman E, Elhan AH, Gok H, Kucukdeveci AA. Does extracorporeal shock wave therapy decrease spasticity of ankle plantar flexor muscles in patients with stroke: A randomized controlled trial. Clin Rehabil. 2021 Oct;35(10):1442-1453. doi: 10.1177/02692155211011320. Epub 2021 Apr 28.
Yang E, Lew HL, Ozcakar L, Wu CH. Recent Advances in the Treatment of Spasticity: Extracorporeal Shock Wave Therapy. J Clin Med. 2021 Oct 14;10(20):4723. doi: 10.3390/jcm10204723.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
University of Health Sciences
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.